Evidence map›Paper›PMID 32448168›Full record

ArticleBMC cancer2020

LRIG1 gene copy number analysis by ddPCR and correlations to clinical factors in breast cancer.

Mahmood Faraz, Andreas Tellström, Christina Edwinsdotter Ardnor, Kjell Grankvist, Lukasz Huminiecki, Björn Tavelin, Roger Henriksson, Håkan Hedman, Ingrid Ljuslinder

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Mahmood FarazDepartment of Radiation Sciences, Oncology, Umeå University, SE-90187, Umeå, Sweden.
Andreas TellströmDepartment of Radiation Sciences, Oncology, Umeå University, SE-90187, Umeå, Sweden.
Christina Edwinsdotter ArdnorDepartment of Radiation Sciences, Oncology, Umeå University, SE-90187, Umeå, Sweden.
Kjell GrankvistDepartment of Medical Biosciences, Umeå University, SE-90187, Umeå, Sweden.
Lukasz HuminieckiNational Bioinformatics Infrastructure Sweden, SciLifeLab, Uppsala, Sweden.
Björn TavelinDepartment of Radiation Sciences, Oncology, Umeå University, SE-90187, Umeå, Sweden.
Roger HenrikssonDepartment of Radiation Sciences, Oncology, Umeå University, SE-90187, Umeå, Sweden.
Håkan HedmanDepartment of Radiation Sciences, Oncology, Umeå University, SE-90187, Umeå, Sweden.
Ingrid LjuslinderDepartment of Radiation Sciences, Oncology, Umeå University, SE-90187, Umeå, Sweden. ingrid.ljuslinder@umu.se.ORCID http://orcid.org/0000-0002-5046-1820
Umeå University · SEScience for Life Laboratory · SE

Funding

Cancer Research Foundation in Northern Sweden LP 16 2139
6 · The paper itself

Abstract

backgroundLeucine-rich repeats and immunoglobulin-like domains 1 (LRIG1) copy number alterations and unbalanced gene recombination events have been reported to occur in breast cancer. Importantly, LRIG1 loss was recently shown to predict early and late relapse in stage I-II breast cancer.

methodsWe developed droplet digital PCR (ddPCR) assays for the determination of relative LRIG1 copy numbers and used these assays to analyze LRIG1 in twelve healthy individuals, 34 breast tumor samples previously analyzed by fluorescence in situ hybridization (FISH), and 423 breast tumor cytosols.

resultsFour of the LRIG1/reference gene assays were found to be precise and robust, showing copy number ratios close to 1 (mean, 0.984; standard deviation, +/- 0.031) among the healthy control population. The correlation between the ddPCR assays and previous FISH results was low, possibly because of the different normalization strategies used. One in 34 breast tumors (2.9%) showed an unbalanced LRIG1 recombination event. LRIG1 copy number ratios were associated with the breast cancer subtype, steroid receptor status, ERBB2 status, tumor grade, and nodal status. Both LRIG1 loss and gain were associated with unfavorable metastasis-free survival; however, they did not remain significant prognostic factors after adjustment for common risk factors in the Cox regression analysis. Furthermore, LRIG1 loss was not significantly associated with survival in stage I and II cases.

conclusionsAlthough LRIG1 gene aberrations may be important determinants of breast cancer biology, and prognostic markers, the results of this study do not verify an important role for LRIG1 copy number analyses in predicting the risk of relapse in early-stage breast cancer.

Indexed as

Gene DosageBiomarkers, TumorBreast NeoplasmsCase-Control StudiesErb-b2 Receptor Tyrosine KinasesFemaleFollow-Up StudiesHumansIn Situ Hybridization, FluorescenceMembrane GlycoproteinsMiddle AgedNeoplasm Recurrence, LocalPolymerase Chain ReactionPrognosisSurvival RateBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesLRIG1 protein, humanMembrane GlycoproteinsBreast cancerddPCRGene copy numberLRIG1Prognosis

Identifiers

PMID32448168
PMCPMC7245921
OpenAlexW2803443284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.